Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy

Clark, 2005, Soft-tissue sarcomas in adults, N Engl J Med, 353, 701, 10.1056/NEJMra041866 Blay, 2003, Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy, Eur J Cancer, 39, 64, 10.1016/S0959-8049(02)00480-X Penel, 2011, Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years, Ann Oncol, 22, 1266, 10.1093/annonc/mdq608 Garcia-Carbonero, 2004, Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy, J Clin Oncol, 22, 1480, 10.1200/JCO.2004.02.098 Le Cesne, 2005, Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial, J Clin Oncol, 23, 576, 10.1200/JCO.2005.01.180 Yovine, 2004, Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients, J Clin Oncol, 22, 890, 10.1200/JCO.2004.05.210 Van Glabbeke, 2001, Progression free rate as the principal end-point for phase II trial on soft tissue sarcoma: what should be the target? A retrospective study of the EORTC soft tissue and bone sarcoma (STBSG) database, J Clin Oncol, 20, 354 Krasner, 2007, A phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens, Br J Cancer, 17, 1618, 10.1038/sj.bjc.6604088 Demetri, 2009, Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules, J Clin Oncol, 27, 4188, 10.1200/JCO.2008.21.0088 del Campo, 2009, Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer, Ann Oncol, 20, 1794, 10.1093/annonc/mdp198 Van Glabbeke, 2002, Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas, Eur J Cancer, 38, 543, 10.1016/S0959-8049(01)00398-7 Cousin, 2012, A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials, Curr Opin Oncol, 24, 338, 10.1097/CCO.0b013e3283528b73 Verweij, 2008, Other endpoints in screening studies for soft tissue sarcomas, Oncologist, 13, 27, 10.1634/theoncologist.13-S2-27 Mehrabi, 2006, Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy, Cancer, 107, 2108, 10.1002/cncr.22225 Penel, 2008, Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study, J Clin Oncol, 26, 5269, 10.1200/JCO.2008.17.3146 Sleijfer, 2009, J Clin Oncol, 27, 3126, 10.1200/JCO.2008.21.3223 Maki, 2009, Phase II study of sorafenib in patients with metastatic or recurrent sarcomas, J Clin Oncol, 27, 3133, 10.1200/JCO.2008.20.4495 Grosso, 2007, Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study, Lancet Oncol, 8, 595, 10.1016/S1470-2045(07)70175-4 Italiano, 2011, Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival, Ann Oncol, 23, 1601, 10.1093/annonc/mdr485 Von Hoff, 1998, There are no bad anticancer agents, only bad clinical trial designs––twenty-first Richard and Hinda Rosenthal Foundation Award Lecture, Clin Cancer Res, 4, 1079 Zalcberg, 2005, Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg, Eur J Cancer, 41, 1751, 10.1016/j.ejca.2005.04.034 Bonetti, 2001, Use of the ratio of time to progression following first- and second-line therapy to document the activity of the combination of oxaliplatin with 5-fluorouracil in the treatment of colorectal carcinoma, Ann Oncol, 12, 187, 10.1023/A:1008354909478 Comella, 2002, Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients, Br J Cancer, 86, 1871, 10.1038/sj.bjc.6600414 Mick, 2000, Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint, Control Clin Trials, 21, 343, 10.1016/S0197-2456(00)00058-1 Kovalchik, 2011, Statistical methods for a phase II oncology trial with a growth modulation index (GMI) endpoint, Contemp Clin Trials, 32, 99, 10.1016/j.cct.2010.09.010 Penel, 2011, Br J Cancer, 104, 1544, 10.1038/bjc.2011.136 Von Hoff, 2010, Pilot study using molecular profiling of patients tumors to find potential targets and select treatments for their refractory cancers, J Clin Oncol, 28, 4877, 10.1200/JCO.2009.26.5983 Debiec-Rychter, 2006, KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours, Eur J Cancer, 42, 1093, 10.1016/j.ejca.2006.01.030 Germano, 2010, Antitumor and anti-inflammatory effects of trabectedin on human myxioid liposarcoma cells, Cancer Res, 70, 2235, 10.1158/0008-5472.CAN-09-2335